[Drug Discovery Seminars] Targeting the oncogenic TGFβ signaling pathway in cancer to inhibit invasion and metastasis
October 28 @ 13:00 – 14:00 CEST
Maréne Landström
October 28, 13:00-14:00
Welcome to join this Drug Discovery Seminar hosted by the Drug Discovery and Development Platform.
Presenter:
Professor Maréne Landström, M.D., PhD
Dept. Medical Biosciences, Umeå University
Maréne Landström is a professor in Pathology at Department of Medical Biosciences, Umeå University, Sweden. She has made her postdoctoral training at the Ludwig Institute of Cancer Research, Uppsala Branch and have also been a group leader at Department of Immunology, Genetics and Pathology, Uppsala University before taking on her current position.
Abstract:
Transforming growth factor beta (TGFb) is frequently overexpressed in several forms of cancer including prostate cancer and this has been shown to correlate with poor prognosis. TGFb is transducing its canonical and non-canonical signals via its transmembrane TGFb Type II and Type I receptors (TbRII/TbRI) which are serine-threonine kinases. We have found that the TbRI undergoes proteolytic cleavage in cancer cells in a manner dependent on the ubiquitin-ligase tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6). The intracellular domain of TbRI (TbRI-ICD) is released from the cell membrane, soluble and is transported to the nucleus in some specific forms of cancer to promote expression of genes causing invasion and metastatic growth. In collaboration with SciLifeLab DDD we have generated potential therapeutic antibodies to target this pathway which we are investigating the function of, in our established preclinical models for prostate cancer.
Google Calendar 
